Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in two upcoming investor conferences in March 2026, signaling the company's continued engagement with the investment community following the recent approval of its flagship product. Seth Lederman, M.D., president and chief executive officer, will deliver a company presentation at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026, from 11:10 a.m. to 11:40 a.m. ET at the Boston Marriott Copley Place in Boston. In addition, management will participate in one-on-one meetings at the Barclays 28th Annual Healthcare Conference, scheduled for March 10-12, 2026, at the Loews Miami South Beach Hotel in Miami Beach.
These conference appearances come at a pivotal time for Tonix, which recently received FDA approval for TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in more than 15 years. The company is now focusing on maximizing the science behind TONMYA through Phase 2 clinical trials evaluating its potential in major depressive disorder and acute stress disorder. This expansion of indications could significantly broaden the drug's market potential and address substantial unmet medical needs in CNS disorders.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company with a focus on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace SymTouch and Tosymra. Beyond TONMYA, the company's CNS pipeline includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In immunology, Tonix is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The company's participation in these high-profile conferences provides an opportunity to update investors on commercial progress and pipeline developments. The TD Cowen and Barclays conferences attract institutional investors and analysts focused on healthcare, offering Tonix a platform to highlight its integrated commercial infrastructure and the potential of its broader pipeline. For more details, the full press release is available at https://ibn.fm/TToz2.
Tonix's recent approval of TONMYA marks a significant milestone for the company and for fibromyalgia patients who have had limited treatment options. The drug's unique sublingual formulation and mechanism of action differentiate it from existing therapies. As Tonix continues to explore additional indications for TONMYA and advance its pipeline, the company's presence at these conferences underscores its commitment to addressing high unmet medical needs in both CNS and immunology.
